RxDoctor Payments Data

Nathaniel Sparks, MD

Family Medicine · Belmont, MSNPI 1720602295

Payments from drug & device makers

$785in general payments, 2019–2025

Across 52 payments — averaging $15.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$390
  • Insulet Corporation$130
  • Novo Nordisk$61
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$49
  • AstraZeneca$49
  • Exact Sciences$37
  • plus $69 from 4 others

What the payments were for

  • Food & beverage$785100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$785 in reported general payments places this provider in the 55th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$36,372
Medicare patients
137
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$77,116
FarxigaDapagliflozin Propanediol58$42,929
JardianceEmpagliflozin51$40,559
EliquisApixaban26$19,572
Tresiba Flextouch U-200Insulin Degludec15$18,924
LinzessLinaclotide20$14,775
XareltoRivaroxaban22$11,828
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,249
Xigduo XrDapaglifloz Propaned/Metformin11$8,018
Tresiba Flextouch U-100Insulin Degludec15$7,512
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$4,175
Dexlansoprazole DrDexlansoprazole16$2,286
Gabapentin153$2,119
Albuterol Sulfate HfaAlbuterol Sulfate32$1,389
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen84$1,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$61$77,11658 claims
AstraZenecaFarxiga, Breztri Aerosphere$49$51,17871 claims
AbbVieLinzess$390$14,77520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Belmont

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →